ArticleBMC infectious diseases2026
Diagnostic performance of procalcitonin for predicting bloodstream infection and guidance on microbial aetiology: a prospective study at an Egyptian tertiary care hospital.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood stream infection (BSI) is a life-threatening condition that implies prompt diagnosis and management. With the time-consuming traditional microbiological culture and limited provision of molecular diagnostics, procalcitonin (PCT) has emerged as a rising rapid biomarker for prediction of BSI.
aimWe aimed to evaluate the diagnostic performance of PCT in predicting BSI as well as in tentative differentiation of the possible underlying microbial etiology.
methodsBlood samples were collected from total 328 patients suspected of having BSI and were measured for levels of procalcitonin, C-reactive protein (CRP) and total leucocyte count (TLC). Concomitant microbiological culture was done for detection and identification of microbial etiology.
resultsMicrobial cultures were positive in 47.9% and negative in 52.1% of patients. Bacterial and fungal growth accounted for 87.8% and 12.1%, respectively, where bacterial growth was differentiated as Gram-positive and Gram-negative bacteria. Culture-positive group displayed significantly higher median values of PCT (2.69 ng/ml) and CRP (117.2 ng/ml) than culture-negative group. PCT levels were significantly higher among Gram-negative than Gram-positive cultures, however were non-significantly higher among bacterial than fungal positive-cultures. Compared to other biomarkers, PCT displayed the highest diagnostic accuracy in differentiating culture-positive and -negative BSI (ROC-AUC: 0.706, P < 0.001) at cut-off value of 0.675 ng/ml, as well as in discriminating Gram-negative and Gram-positive bacteria (ROC-AUC:0.636, P: 0.004) at cut-off value of 2.135 ng/ml.
conclusionPCT exhibited higher diagnostic accuracy than other biomarkers in BSI and in differentiating Gram-negative and Gram-positive bacterial etiology, which may offer a modest guidance in sepsis management and optimization of antibiotic intake. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.